Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patients with recurrent high grade gliomas treated with lapatinib monotherapy and temozolomide plus lapatinib combination to investigate the safety and efficacy of the combination.

Next Previous
Trial Profile

Patients with recurrent high grade gliomas treated with lapatinib monotherapy and temozolomide plus lapatinib combination to investigate the safety and efficacy of the combination.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 14 Dec 2017 Status changed from active, no longer recruiting to completed.
  • 24 May 2012 Planned number of patients changed from 74 to 66 as reported by Australian New Zealand Clinical Trials Registry.
  • 27 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top